High-dose-rate brachytherapy lowers travel burden for men with localized prostate cancer compared with external beam radiation
HDR-BT monotherapy significantly reduces the travel burden compared with EBRT for localized prostate cancer, with minimal treatment-associated toxicity. Increasing the availability of BT centers could further alleviate the travel burden. Alternatively, providing transportation support could improve access to care.
Authors
- Kevin Bylund (ORCID: https://orcid.org/0000-0003-2484-1261)
- Hongmei Yang (ORCID: https://orcid.org/0000-0003-0924-5795)
- Michael P. Cummings (ORCID: https://orcid.org/0000-0002-1467-0334)
- Hong Zhang (ORCID: https://orcid.org/0000-0003-3631-9163)
- Catherine Liu (ORCID: https://orcid.org/0000-0002-7532-4822)
Institutions
- University of Rochester Medical Center (US)
- University of Rochester (US)
Publication Details
- Journal
- Frontiers in Urology
- Published
- 2025-06-30
- DOI
- https://doi.org/10.3389/fruro.2025.1598726
- Citations
- 1
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.52